- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04742686
Aerobic Exercise Training in Acute Ischaemic Stroke (ATAS)
Aerobic Exercise Training in Acute Ischaemic Stroke: A Single-centre, Single-blinded, Randomised, Controlled Feasibility Study of an Aerobic Exercise Training Intervention Versus Standard Care Conducted in the Acute Phase of Stroke.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction
Pre-clinical studies indicate that aerobic exercise training can enhance brain repair and reduce disability when initiated early (1-7 days) after stroke. However, in the real-world clinical setting, most acute stroke patients have a lower-limb disability which makes it difficult to engage in aerobic exercise. Power-assisted exercise bikes can detect lower-limb motor deficits and compensate with motorised assistance. The primary aim of this study is to assess the feasibility of implementing a 5-day power-assisted aerobic exercise training programme, initiated in the acute phase of ischaemic stroke (1-7 days post-stroke). Key feasibility outcomes related to the intervention include safety (<10 adverse events related to the intervention) and acceptability (>3/5 comfort scale). The secondary aim is to assess the feasibility of conducting a randomised controlled trial (RCT), with a focus on study procedures including recruitment (30 participants recruited within 18 months) and completeness of data (≥80% of planned measurements recorded), and identification of a suitable primary outcome measure for a large-scale RCT.
Recruitment
People with acute ischaemic stroke admitted to the Royal Hallamshire Hospital (Sheffield, England) will be recruited to this study. After eligible individuals provide informed consent, a web-based permuted block randomisation procedure will be used to allocate participants into one of two study arms: 1) usual care; or 2) aerobic exercise training plus usual care. Participants will be stratified using the National Institutes of Health Stroke Scale (NIHSS): mild to moderate (0-15) and moderate to severe (>15) measured after reperfusion therapy or at a similar timepoint if not eligible for reperfusion therapy. Accounting for a predicted attrition rate of 20%, the target sample size is 30 participants.
Intervention
A bedside power-assisted exercise bike will be used to enable patients to undertake aerobic exercise whilst remaining in their bed, even if they have a lower-limb disability. The aerobic exercise programme will consist of five exercise sessions, each including a graduated warm-up, a conditioning phase, and a graduated cooldown. The conditioning phase will be an interval training format, with five-minute low- to moderate-intensity intervals interspersed with one-minute rest periods. The number of five-minute conditioning bouts will increase by one bout per session. The first session will contain two bouts (total = 10 mins), and the fifth session will contain six bouts (total = 30 mins). The rationale for this progressive design was developed with input from researchers, healthcare practitioners and people affected by stroke. Briefly, it was considered that starting with 30 minutes of aerobic exercise in the first session may be too difficult for some patients due to fatigue, whereas a gradual progression in exercise duration would be more tolerable. In addition, the interval training design was chosen to reduce exercise-induced fatigue, and thereby increase the total duration of aerobic exercise completed per session. Participants will cycle at a steady self-selected cadence, and exercise intensity will be guided by the Borg rating of perceived exertion (RPE) scale. During the conditioning intervals, participants will be asked to the cycle at an intensity equivalent to 'somewhat hard' (RPE:13/20). Heart rate, peripheral oxygen saturation, brachial blood pressure, and symptoms will be monitored throughout each exercise session. In the fourth or fifth exercise session, exercise-induced changes in respiratory gases, cerebral blood flow velocity and blood-borne brain-derived neurotrophic factor will be assessed. Established clinical exercise physiology guidelines will be followed with regards to exercise contraindications and termination criteria.
Usual care
Participants randomised to the control group will receive usual care according to guidance from the National Institute for Health and Care Excellence and the Royal College of Physicians. Briefly, it is recommended that patients undertake at least 45 minutes of each appropriate therapy per day (physiotherapy, occupational therapy and or speech and language therapy) for five days per week. Patients should be mobilised (out-of-bed sitting, standing or walking) within the first 48 hours of stroke onset, or if physically capable, as soon as possible post-stroke.
Interviews
7-14 days after enrolling in the study, a convenience sample of participants (n=8 per study arm) will be interviewed to gain insight into participants' experiences participating in the study activities (e.g. intervention and or assessments). Repeat interviews will be conducted with the same individuals three months later with a focus on their post-hospital rehabilitation experiences. In addition, a small convenience sample (n=3-5) of clinical staff members will be interviewed to understand their opinions about the intervention and overall study procedures.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S10 2JF
- Royal Hallamshire Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult (age >18 years) patients diagnosed with acute ischaemic stroke 1-7 days previously.
- Medically stable, assessed by a stroke physician.
- Sufficient English language comprehension and cognitive ability to understand the study protocol, follow instructions, complete questionnaires and give informed consent.
- Ability to mobilise lower body limbs in a cyclical manner (at least one leg).
- Likely to be admitted to the Royal Hallamshire Hospital for at least 7 days.
Exclusion Criteria:
- Haemorrhagic stroke.
- <1 day or >7 days after onset of stroke symptoms.
- Clinically unstable, assessed by stroke physician.
- Disability preventing unipedal cycling.
- New York Heart Failure Classification stage III/IV.
- Terminal illness (life expectancy <6 months).
- Resting blood pressure >180/110 mmHg.
- Uncontrolled arrhythmia causing symptoms or haemodynamic compromise.
- Unstable angina.
- Uncontrolled diabetes mellitus.
- Acute deep vein thrombosis, pulmonary embolism or pulmonary infection.
- Already participating in a clinical research trial.
- Pain during mobilisation of lower-limbs.
- Lower-limb spasticity or contracture which impairs ability to cycle.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
|
5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme.
Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
|
|
No Intervention: Usual care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of aerobic exercise training
Time Frame: 21 months
|
The following traffic light-style system is proposed:
|
21 months
|
|
Acceptability of aerobic exercise training
Time Frame: 18 months
|
Average comfort score > 3/5 Likert scale (1= very uncomfortable to 5= very comfortable)
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of recruitment
Time Frame: 18 months
|
Recruitment rate: ≥2 participants per month (30 participants recruited in 18 months)
|
18 months
|
|
Feasibility of data collection
Time Frame: 21 months
|
Completeness of data: ≥80% of planned measurements recorded
|
21 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rectus femoris cross sectional area
Time Frame: Baseline, 1 week and 3 months
|
Rectus femoris cross sectional area measured using ultrasound
|
Baseline, 1 week and 3 months
|
|
Rectus femoris muscle thickness
Time Frame: Baseline, 1 week and 3 months
|
Rectus femoris muscle thickness measured using ultrasound
|
Baseline, 1 week and 3 months
|
|
Vastus lateralis muscle thickness
Time Frame: Baseline, 1 week and 3 months
|
Vastus lateralis muscle thickness measured using ultrasound
|
Baseline, 1 week and 3 months
|
|
Vastus lateralis angle of pennation
Time Frame: Baseline, 1 week and 3 months
|
Vastus lateralis angle of pennation measured using ultrasound
|
Baseline, 1 week and 3 months
|
|
Cognitive function
Time Frame: Baseline, 3 months
|
Montreal Cognitive Assessment
|
Baseline, 3 months
|
|
Anxiety and depression
Time Frame: 1 week, 3 months
|
Hospital Anxiety and Depression Scale
|
1 week, 3 months
|
|
Optimism
Time Frame: Baseline, 3 months
|
Revised Life Orientation Test
|
Baseline, 3 months
|
|
Exercise self-efficacy
Time Frame: Baseline, 1 week and 3 months
|
Self-Efficacy for Exercise Scale
|
Baseline, 1 week and 3 months
|
|
Health-related quality of life
Time Frame: Baseline, 3 months
|
EuroQol 5-Dimensional
|
Baseline, 3 months
|
|
Inpatient physical activity levels
Time Frame: Worn for 1 week in hospital
|
Thigh-mounted accelerometer
|
Worn for 1 week in hospital
|
|
Post-discharge physical activity levels (short-term)
Time Frame: Worn for 2 weeks post-discharge
|
Wrist-worn accelerometer
|
Worn for 2 weeks post-discharge
|
|
Post-discharge physical activity levels (long-term)
Time Frame: 3 months
|
Global Physical Activity Questionnaire
|
3 months
|
|
Chronic fatigue
Time Frame: Baseline, 3 months
|
Chronic Fatigue Scale
|
Baseline, 3 months
|
|
Lower-extremity function
Time Frame: Baseline, 1 week and 3 months
|
Short physical performance battery (standing balance, sit-to-stand, 3-metre walk)
|
Baseline, 1 week and 3 months
|
|
Upper-extremity function
Time Frame: Baseline, 1 week and 3 months
|
Handgrip strength (dynamometer)
|
Baseline, 1 week and 3 months
|
|
Disability
Time Frame: Baseline and 3 months
|
Modified Rankin Scale
|
Baseline and 3 months
|
|
Functional independence
Time Frame: Baseline, 4-8 weeks, 3 months
|
Barthel Index
|
Baseline, 4-8 weeks, 3 months
|
|
Aerobic exercise-induced changes in cerebral blood flow velocity
Time Frame: Day 5 or 6 (measured for approximately 1 hour during exercise session)
|
Mean cerebral blood flow velocity, measured bilaterally at the middle cerebral arteries using transcranial Doppler ultrasound
|
Day 5 or 6 (measured for approximately 1 hour during exercise session)
|
|
Aerobic exercise-induced changes in mature brain-derived neurotrophic factor (BDNF)
Time Frame: Day 5 or 6 (pre-post exercise)
|
Blood collection at rest and within 5 minutes of ceasing aerobic exercise session.
Serum and plasma BDNF will be measured using enzyme-linked immunosorbent assays
|
Day 5 or 6 (pre-post exercise)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tom Maden-Wilkinson, PhD, Sheffield Hallam University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH21298
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
We will have exclusive access to the data for 24 months after the end date of the study whilst we develop a protocol and grant application, and publish our findings.
Data will be accessible before 24 months should these objectives be achieved earlier than expected. Anonymised data will be provided on application rather than be offered open access. A description of the data will be placed on the University open access repository (SHURDA).
Data sharing will be subject to an application. No sensitive/personal data will be made available.
All external users of our data will be bound by a data sharing agreement between the research team, the University, and the user themselves. Data will be supplied on the condition that their research is non-profit, and that their findings will be published in an open access domain. Data users will not be permitted to share the data with anyone outside of their immediate research team.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
University Hospital HeidelbergCompletedAcute Ischemic Stroke | Acute Ischemic Stroke AIS | Acute Ischemic Stroke PatientsGermany
-
University of CalgaryThe George Institute for Global Health, AustraliaRecruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Kessler FoundationNational Institute on Disability, Independent Living, and Rehabilitation...RecruitingStroke | Stroke Gait Rehabilitation | Stroke Ischemic | Balance Deficits | Stroke (CVA) or Transient Ischemic AttackUnited States
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of MiamiNo longer availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
Jagiellonian UniversityCompletedStroke, Ischemic | Subacute StrokePoland
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
Clinical Trials on Aerobic exercise training
-
UNC Lineberger Comprehensive Cancer CenterCompletedStem Cell Transplantation, HematopoieticUnited States
-
Gazi UniversityActive, not recruiting
-
National Taiwan University HospitalCompletedAtrial FibrillationTaiwan
-
Riphah International UniversityCompletedSpinal Cord InjuriesPakistan
-
Istinye UniversityNot yet recruitingCOPD (Chronic Obstructive Pulmonary Disease)
-
Bezmialem Vakif UniversityThe Scientific and Technological Research Council of TurkeyCompletedDown Syndrome | Cognitive Function | Functional Capacity | Aerobic Exercise | Physical Fitness | Virtual Reality Based Therapy | ExergameTurkey (Türkiye)
-
Istanbul University - Cerrahpasa (IUC)CompletedObstructive Sleep Apnea SyndromeTurkey
-
University of HoustonTerminated
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalUnknownStroke Patients With Cognitive DeclineTaiwan